There are 383 resources available
34P - RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions
Presenter: Arianna Marinello
Session: Poster Display session
35P - Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations (ex20ins)
Presenter: Tae Min Kim
Session: Poster Display session
36P - Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
Presenter: Petros Christopoulos
Session: Poster Display session
37P - Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
Presenter: Ali Chour
Session: Poster Display session
38P - The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
Presenter: Lucia Notario Rincon
Session: Poster Display session
39P - Determination of essential biomarkers in lung cancer: A real-world data study in Spain
Presenter: Virginia Calvo de Juan
Session: Poster Display session
40P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis
Presenter: Giulia Pretelli
Session: Poster Display session
41P - Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world study
Presenter: Talia Shentzer Kutiel
Session: Poster Display session
42P - Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low
Presenter: Ilaria Attili
Session: Poster Display session